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There is an emerging need for new animal models that address unmet translational
cancer research requirements. Transgenic porcine models provide an exceptional
opportunity due to their genetic, anatomic, and physiological similarities with humans.
Due to recent advances in the sequencing of domestic animal genomes and the
development of new organism cloning technologies, it is now very feasible to utilize pigs
as a malleable species, with similar anatomic and physiological features with humans,
in which to develop cancer models. In this review, we discuss genetic modification
technologies successfully used to produce porcine biomedical models, in particular
the Cre-loxP System as well as major advances and perspectives the CRISPR/Cas9
System. Recent advancements in porcine tumor modeling and genome editing will bring
porcine models to the forefront of translational cancer research.
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INTRODUCTION
Animal models have played a central role over the centuries in scientific investigations of human
disease and treatment strategies. Genetic strategies for the development of cancer models using
human mutations in targeted oncogenic pathways demonstrated that porcine fibroblasts could be
transformed in vitro and could be tumorigenic with four to six gene alterations (Adam et al., 2007).
The authors used retroviral vectors carrying pairs of human and murine oncogenic cDNAs (hTERT
and p53DD, cyclin D1 and CDK4R24C, and c-MycT58A, and H-RasG12V) to transform porcine
fibroblasts. These altered cells showed a transformed phenotype in culture and formed tumors
following autologous transfer. These induced changes demonstrated that the pig/tumorigenic
pathway recapitulated those observed in human much more closely than murine cells (Adam et al.,
2007). Although this approach was limited because the animals needed to be immuno-suppressed
for tumors to grow in vivo, this work was the first to demonstrate that genetically defined tumors
could be induced in a large animal (Schook et al., 2015a).
Recent innovations in reproductive, cloning and transgene technologies have enhanced efficacy
and efficiency or producing targeted porcine genome modifications. With the successful cloning
of animals by somatic cell nuclear transfer (SCNT), it is now possible to produce genetically
modified pigs from genetically engineered somatic donor cells using a wide variety of techniques
from random genomic insertion of plasmid DNA (Hyun et al., 2003; Watanabe et al., 2005), to
genomic integration of transduced retroviral or lentiviral vectors (Lai et al., 2002; Park et al., 2002),
and to modern genome editing with molecular methods using endonucleases such as transposases,
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recombinases, and programmable nucleases (Zhou et al., 2015).
Genetic modification technologies successfully used to produce
porcine biomedical models, in particular the Cre-loxP System as
well as major advances and perspectives the CRISPR/Cas9 System
will be presented in this mini review.
Cre-loxP SYSTEM
The ability to activate latent genes in defined tissues and at
defined times is a key factor to enable the development of
inducible temporally and spatially regulated cancer models. The
activation of an oncogenic mutation(s) in a chosen tissue could
mimic the spontaneous somatic events that initiate many human
cancers and enable replication of diverse cancer types using the
same mutant gene(s) (Flisikowska et al., 2013). Those conditional
gene expressions are now well established in mice using site-
specific recombinase (SSR) systems that allow the precise
recombination between genomic sites, resulting in deletion or
inversion of the intervening sequences (Frese and Tuveson,
2007; Oh-McGinnis et al., 2010). The use of SSR technology
in genome manipulation has been demonstrated to effectively
resolve complex transgene insertions to single copy, remove
unwanted DNA, and precisely insert DNA into known genomic
target sites (Wang et al., 2011). Site-specific recombination occurs
at a specific sequence or recognition site and involves cleavage
and reunion leading to integration, deletion or inversion of a
DNA fragment without the gain or loss of nucleotides (Wang
et al., 2011). Because of the efficiency of the SSR systems, it
can be applied to conditional deletions of relatively short coding
sequences or regulatory elements but also to more extensive
chromosomal rearrangement strategies (Oh-McGinnis et al.,
2010).
Cre-recombinase system is one of the best-studied and
most commonly used SSR in mammalian cell cultures. Since
its first use for mammalian genome editing in 1988 (Sauer
and Henderson, 1988) many adaptations have expanded the
utility of the Cre system from flies to mammalian cells beyond
mouse to include porcine and humans cell lines (Lanza et al.,
2012). Cre-recombinase is derived from the bacteriophage P1
and recognizes a distinct sequence-specific motif termed as
recombination target sites (loxP) catalyzing efficient conservative
DNA rearrangements (Wirth et al., 2007). The loxP site is a
34 bp palindromic sequence with an 8-bp asymmetric spacer
region (Feng et al., 1999; Siegel et al., 2001; Araki et al., 2002;
Sauer, 2002; Schnutgen et al., 2003; Garcia-Otin and Guillou,
2006) and acts upon the neighboring DNA sequences. The
Cre-loxP system is a bidirectional tyrosine recombinase that
enables the recombinase-mediated genetic cross-over between
two identical loxP recognition sites promoting intermolecular or
intramolecular recombination. Intermolecular recombination is
a translocation between two DNA fragments with corresponding
loxP sites, while the intramolecular recombination involves
removal of genetic material between two loxP sites, with the
last one been the preferred function of Cre-recombinase (Feng
et al., 1999). Because of the identical nature of the recognition
sites, the recombination reaction is fully reversible, although
intramolecular recombination (excision) is highly favored over
intermolecular reactions (integration) (Wang et al., 2011).
One of the most powerful and widely used applications of
the Cre/loxP system is in conditional gene expression (Gu et al.,
1994). This strategy allows for tissue and time-specific gene
expression when recombination is triggered by Cre-recombinase,
and is even more important in cancer models where oncogenic
activation in a chosen tissue could mimic the spontaneous
somatic events that initiate many human cancers (Schook et al.,
2015a). Endogenous engineered mice are usually conditional
alleles constructed by the insertion of a transcriptional and
translational LoxStopLox ‘stop’ cassette between the promoter
and first coding exon of the oncogenic allele. Providing the
expression of an active Cre-recombinase, the stop cassette is
excised and the mutant oncogene is subsequently expressed
(de Alboran et al., 2001; Jackson et al., 2001). In pigs, this
conditional gene expression strategy has been used to promote
oncogenic expression in three cancer models (Leuchs et al.,
2012; Li et al., 2015; Schook et al., 2015b). Leuchs et al. (2012)
have generated gene-targeted pigs with a conditionally activated
oncogenic mutant form of p53, which in latent form is a gene
knockout. The construction used a porcine BAC vector with
CAGGS promoter-mCherry cassette (in reverse orientation) as a
fluorescent counter-selectable marker; a short arm of homology
corresponding to a region of TP53 intron 1 from a point
of exon 2 to a PmlI restriction enzyme site of exon 2; a
floxed transcriptional termination cassette (LSL); and a region
extending from the PmlI site in intron 1 to a point of exon
11 that includes a G to A substitution in exon 5 changing
arginine to histidine in codon 167 (R167H) (Leuchs et al.,
2012). In this same model, viable gene-targeted pigs carrying a
latent KrasG12D mutant allele that could be activated by Cre-
recombinase was constructed (Li et al., 2015). The KRAS-neo
vector comprised: a short homology arm in KRAS intron 1; a
transcriptional stop cassette comprising: a loxP site; adenoviral
splice acceptor; promoterless neomycin phosphotransferase
resistance gene (neo); three poly-adenylation signals derived
from SV40, bovine growth hormone and cytomegalovirus; and
a second loxP site inserted into a ClaI site in KRAS intron 1; and
a region of porcine KRAS extending from the ClaI site in intron
1 to a SacI site in intron 2, which also included an engineered
G to A point mutation within exon 2 that results in a glycine to
aspartic acid substitution at codon 12 (G12D) (Li et al., 2015).
Both KRAS and TP53 transgenic pigs cells were transduced with
5 µM of Cre protein produced in vitro with the vector pTriEx-
HTNC (Addgene plasmid 13763; Leuchs et al., 2012; Li et al.,
2015).
Transgenic oncopigs (Figure 1) have also been engineered
to contain oncogenic KrasG12D and dominant-negative p53R167H
downstream of a LoxP-polyA(STOP)-LoxP sequence (LSL) and
CAG promoter (Schook et al., 2015b). Site-directed mutagenesis
was then used to introduce the oncogenic G12D mutation into
the porcine KRAS cDNA and the R167H mutation was chosen
for TP53 as its human equivalent (R175H) is commonly found in
human cancers as well as the cancer predisposition Li-Fraumeni
Syndrome. These two cDNAs were then introduced into a Cre-
inducible vector, followed by the aforementioned LSL sequence,
Frontiers in Genetics | www.frontiersin.org 2 February 2016 | Volume 7 | Article 28
fgene-07-00028 February 26, 2016 Time: 16:55 # 3
Schook et al. Inducible Pig Cancer Models
FIGURE 1 | Development of the Oncopig using the Cre-loxP inducible system. Pigs were cloned from fibroblast cells with this transgene construct (A).
Fibroblast cell lines were established from oncopig offspring. In vitro work utilized fibroblast cell lines isolated from transgenic oncopigs which were then infected with
adenovirus encoding Cre recombinase (AdCre) and the marker green fluorescent protein (GFP) (B). AdCre induced removal of the STOP codon allowing for
expression of both transgenes. This expression altered the phenotype of the cells as was demonstrated in numerous in vitro assays (C). Oncopig clones (founders)
were crossbreed with York females (D). The transgenic offspring (Tg) (E) were injected with AdCre at various sites including intramuscular, subcutaneous and
intratesticular sites (F). Tumors were induced at each site of injection in transgenic oncopigs (G).
KRASG12D, an IRES sequence to allow for bicistronic expression,
TP53R167H and a poly A sequence. This design allows for co-
expression of both KRASG12D and TP53R167H in ostensibly any
cells of the pig by transient expression of AdCre (Ad5CMVCre-
eGFP, AdGFP, Gene Transfer Vector Core; Schook et al., 2015b).
These pig models have resulted in tumorigenic profiles in vitro
(Leuchs et al., 2012; Li et al., 2015) and in vivo (Schook et al.,
2015b) and the results obtained with these three cancer pig
models are shown in Table 1.
CRISPR/Cas9 SYSTEM
The discovering of molecules that recognize specific sequences of
DNA was one of the most important advances in gene editing
technology allowing site specific genetic modifications to be
made. These DNA binding proteins include the zinc fingers and
transcriptional activator-like effector (TALE; Wood et al., 2011;
Gaj et al., 2013). When they are fused to nucleases, they generate
a double-strand break (DSB) in the DNA at the desired genomic
loci, triggering the endogenous DNA repair machinery (Gaj
et al., 2013; Zhu et al., 2014); if fused to transcription factors or
inhibitor molecules, they can bind to promoter regions of target
genes, modulating gene expression (Gilbert et al., 2014; Kearns
et al., 2014). However, there is a disadvantage of utilizing these
proteins that interact with DNA: production of these proteins
involves a complicated and more expensive assembly process
(Pan et al., 2014).
An easier, cheaper, and yet highly efficient tool for directed
genome edition appeared to be more worthwhile and profitable
than proteins: the CRISPR (clustered regularly interspaced short
palindromic repeat)/Cas (CRISPR associated proteins) system.
This system is simpler then zinc fingers and TALEs because
the CRISPR/Cas system uses the RNA-DNA interaction for
genome loci recognition, which is more specific than protein-
DNA (Gasiunas and Siksnys, 2013; Pan et al., 2014).
CRISPR/Cas system has been recently discovered as an
adaptive immune system of some bacteria and archaea and
protects them against invading viruses and plasmids (Barrangou
et al., 2007). The transcription of the repeat-spacer elements from
CRISPR locus generates a precursor non-coding CRISPR RNA
(pre-crRNA) that later will be cleaved to have short CRISPR
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RNAs (crRNA) (Garneau et al., 2010; Jinek et al., 2012). The
crRNA will be homologous to the DNA or RNA from foreign
sequences, and when the invasion occurs, the crRNA will be
directed just by Watson-Crick base pairing (Jinek et al., 2012;
Wade, 2015). There are different types of CRISPR systems in
different organisms (I–III), and the one that have been most
developed as a new tool for genome editing, the CRISPR/Cas9
system, is the type II CRISPR originating from Streptococcus
pyogenes SF370 (Jinek et al., 2012; Qi et al., 2013). The type II is
different from types I and III, that crRNA hybridize with another
RNA molecule, the trans-activating crRNA (tracrRNAs), to direct
Cas9 protein to specific DNA sequences (Jinek et al., 2012; Mali
et al., 2013; Doudna and Charpentier, 2014). For genome editing,
the researchers created a single chimeric guide RNA’s (sgRNA),
which is a fusion of a precursor crRNA and a transactivating
crRNA (tracrRNA) (Jinek et al., 2012; Pan et al., 2014). Beyond
the polymerization, the genome sequence from invader has a
complementary genome sequence containing a tri-nucleotide
protospacer adjacent motif (PAM) that will be required for initial
binding of Cas9 protein (Guilinger et al., 2014). Cas9 protein
has an endonuclease activity that cleaves on both strands a few
nucleotides away from the PAM generating DSB, preventing the
invader genome translation (Jinek et al., 2012). This has been
used to generate knockin and knockout transgenic animals, as the
DSB activates the endogenous DNA repair machinery by non-
homologous joining (Ma et al., 2014; Flemr and Buhler, 2015;
Yang, 2015; Zhu et al., 2015).
However, the study of CRISPR/Cas9 identified a new
application for Cas9: without its nuclease activity, Cas9 protein,
attached to a molecule that modulates gene expression, could
bind to the promoter region of some gene of interest, changing
the genic expression pattern (Qi et al., 2013). The catalytically
dead Cas9 (dCas9), lacking endonuclease activity, contains
two mutations in the nuclease domains (D10A and H840A)
(Choudhary et al., 2015). Since dCas9 was reported, new
studies have been described using it for genome regulation
creating different segments to use this tool: CRISPRi, for gene
interference, and CRISPRa, for activation of gene translation.
When these strategies uses an effector domain attached to dCas9,
it can be called CRISPRe. For gene interference (CRISPRi), dCas9
recognizes sgRNA attached to the promoter region of target gene,
impairing transcription (Qi et al., 2013). However, this strategy is
not efficient for gene repression in eukaryotic cells, so dCas9 can
be fused to a transcription repression domain to enhance gene
knockdown (Gilbert et al., 2013). The most described strategy
for CRISPRi is dCas9 fused to a KRAB (Krüppel- associated box
domain of Kox1), a repressive chromatin modifier domain, which
have been demonstrating increased gene expression repression in
relation to dCas9 alone (Gilbert et al., 2013, 2014). Some authors
mention that CRISPRi can be an alternative strategy to RNAi
for repressing gene expression in mammalian cells (Gilbert et al.,
2013).
Another approach for using dCas9 is fused to transcriptional
activator domains, which can be called CRISPRa (Gilbert et al.,
2014) or CRISPR-on system (Cheng et al., 2013a), to induce
expression of target genes. To achieve that, dCas9 fused to the
transcriptional activator is guided by the sgRNA complementary
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to the promoter region of the gene. The well-characterized
tetramer of herpes simplex virus protein, VP16 (VP64) is one
of the most reported transcription activator attached to dCas9
and it has been shown to induce gene expression in eukaryotic
cells, including human cells (Gilbert et al., 2013, 2014; Maeder
et al., 2013; Perez-Pinera et al., 2013; Kearns et al., 2014). Some
studies also report that target genes can be simultaneity artificially
activated by just adding complementary sgRNAs of promoters
of each one of the interest genes (Cheng et al., 2013b; Maeder
et al., 2013). This strategy has been tested in human and mouse
transformed cells, as well as in ES cells, in one-cell embryo (Cheng
et al., 2013b).
The use of CRISPR/Cas9 strategy to build an animal for model
of cancer disease is a recently developed approach. For lung
adenocarcinoma, Maddalo et al. (2014) describe a methodology
of in vivo chromosomal rearrangement using CRISPR/Cas9
delivered by virus infection. Rearranging chromosomes by fusing
EML4 and ALK genes generated a new murine model for lung
adenocarcinoma. An in vivo somatic cancer mutation in adult
animals was described by Xue et al. (2014), which they developed
a different strategy using a hydrodynamic delivery of plasmids
with CRISPR components that occasioned to efficient hepatocyte
transfection to edit oncogenes and suppressor-tumor genes.
Most frequently, rodents are used to test new strategies for
genome editing with CRISPR/Cas9 system to develop cancer
and other biomedical models of human disease. However,
a new strategy for enrichment of cells with chromosomal
deletions made by CRISPR/Cas9 to generate cancer genotype
was developed in porcine embryonic fibroblasts (He et al., 2015).
For employment in xenotransplants, CRISPR/Cas9 technology
has already been applied to inactivate porcine endogenous
retroviruses in porcine kidney epithelial cell line (Yang et al.,
2015).
Not only modifications in genome sequence can induce cancer
phenotype, epigenetic modifications can also be a target to
develop animal models for cancer. Falahi et al. (2015) supposes
that dCas9 can contribute for epigenome engineering to develop
animals for cancer study. Effector domains attached to dCas9
could generate epigenetic mutations known to evolve to different
cancer types. Also using dCas9, attached or not to KRAB domain,
initial studies in human cells HEK293 and HEK293T, showed
repression of TP53 (Lawhorn et al., 2014).
The recent advances generated by CRISPR/Cas9 system in
genome editing are extremely important for development of new
strategies to generate animal models of cancer. The simplicity,
low cost, and low off-target effects put this strategy as one
alternative not only for ZFN and TALEN, but also for RNAi
technology and Cre-loxP systems.
PERSPECTIVES
To unite Cre-loxP and CRISPR/Cas9 system has been a
promising approach to develop animal models for cancer. Cre-
loxP affords to conditional gene expression, while CRISPR/Cas9
can be used for target gene insertion and also for gene expression
regulation. Some promising works already showed how these
technologies can be used together. Using Cre-loxP system
for induced expression, Sánchez-Rivera et al. (2014) used a
system with CRISPR/Cas9 and Cre recombinase to evaluate
new candidates for cancer genome, developing adenocarcinoma
by editing tumor-suppressor genes sequences in mice models.
A different association of both techniques is a study that a
mouse model had Cas9 expressed by Cre dependence, and when
expressed in conjunction with sgRNAs for Kras, p53, and LKB1
genes, it generated a change of function of those proteins, taking
to macroscopic tumors of adenocarcinoma pathology (Platt et al.,
2014). Probably, the next step is to standardize those techniques
and employ them for a next-generation models for human
cancer (Sanchez-Rivera and Jacks, 2015), and pigs fits for those
purpose.
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